Moderna inventory continued a two-day dive Thursday regardless of reporting its first-ever revenue after the primary full quarter of Covid vaccine gross sales lagged forecasts.
Within the first quarter, Moderna (MRNA) posted $1.94 billion in income, together with $1.73 billion in gross sales of its Covid vaccine. However analysts referred to as for $2.06 billion in gross sales, and the disparity slammed Moderna inventory.
Nonetheless, steering for 2021 was sturdy. Moderna expects $19.2 billion in gross sales this 12 months primarily based on its already-scheduled deliveries. And Moderna boosted its outlook for doses manufactured to 800 million this 12